

PRESS RELEASE



Contact Information:

NeoHack Life Sciences, LLC
Ron Butler
Phone: (737) 932-0652
rb@neohacksciences.com

FOR IMMEDIATE RELEASE

NeoHack Life Sciences Opens Licensing Opportunities for its “Restoring Homeostasis: The Next Generation” Program

AUSTIN, TEXAS, July 26, 2023 – NeoHack Life Sciences, LLC announced today that it has opened licensing opportunities for its patent-pending “synergistic compositions” aimed at restoring homeostasis.

NeoHack’s two pending patents are the result of years of research targeting “non-homeostasis”, a serious imbalance in the body’s natural response to injury and the source of many forms of chronic inflammation.

“What we found is that certain natural and nature-identical ingredients—each with valuable inflammation fighting properties—can be strategically combined in a way that causes the resulting product to perform at a markedly higher level than each individual ingredient would,” said Dr. Dale Brown, NeoHack’s Chief Science Officer.

NeoHack’s pending patent points to its formulation’s ability to work directly on “ionotropic cannabinoid receptors” in a way that appears to move the needle on returning the body to homeostasis, or its healthy “set point”.

“By targeting non-homeostasis, patients using NeoHack’s formulation reported longer-lasting relief from-- or at times, a non-recurrence of -- conditions they sought to treat. In some cases, the formulation also appears to have been effective for conditions the patients weren’t seeking to treat,” said Ron Butler, NeoHack’s Chief Executive Officer.

Multiple case studies and reported outcomes appear in both NeoHack patent applications.

“Highly effective, non-addictive pain treatments is just one benefit of NeoHack’s synergistic formulations, and it couldn’t come at a better time in our history,” said Butler. “The greater good will be served by licensing our intellectual property now and encouraging better funded, larger entities to bring our science to bear more quickly and more widely than we are able to do.”

NeoHack will continue its promising research into the ionotropic cannabinoid receptor’s possible role in slowing memory loss in Alzheimer’s patients and addressing chronic pain, itch and wound healing.

###

To discuss licensing opportunities or learn more about NeoHack’s work, please contact one of NeoHack’s Senior Officers at info@neohacksciences.com or [visit its website at www.neohacksciences.com](http://www.neohacksciences.com).